Improving how vasopressors are given to patients with early sepsis
Official title: Optimizing Vasopressor Delivery in Early Sepsis
Funded at University of Michigan at Ann Arbor · NIH-10996104 · Data updated 2026-11-12
This study is looking at how hospitals give important medications called vasopressors to people with severe sepsis and septic shock, to find the best ways to use them and help patients recover better.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project start | December 1, 2023 |
| Project end | January 31, 2025 |
| Funding year | 2025 |
| Award (this year) | $18,548 |
| NIH project number | 5F32HL172463-02 |
| Project ID | NIH-10996104 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with severe sepsis or septic shock who require vasopressor treatment.
✕Less likely to help
Patients with mild infections or those not requiring vasopressor therapy may not benefit from this research.
What this research studies
This research focuses on optimizing the delivery of vasopressors, which are critical medications used to treat severe sepsis and septic shock. The project aims to understand the variations in how these medications are administered in hospitals and how these differences impact patient outcomes. By conducting advanced statistical analyses and randomized surveys, the research will gather data to inform best practices for vasopressor delivery. This work is essential for developing clinical trials that could lead to improved survival rates for sepsis patients.
Why it matters
Potential benefit: If successful, this research could lead to better treatment protocols for sepsis, ultimately improving survival rates and recovery for patients.
How similar studies have gone: Previous research has shown that optimizing medication delivery methods can significantly improve patient outcomes, suggesting a strong potential for success in this area.
Where this research is happening
-
University of Michigan at Ann Arbor
Ann Arbor, United States Active
Researchers
- Principal investigator: Munroe, Elizabeth — University of Michigan at Ann Arbor
- Study coordinator: Munroe, Elizabeth
Related research
Other NIH-funded projects on the same topics.
-
Role of blood flow mechanics and transfusion in sepsis-related tiny-cl vessel clots
A patient-focused look at how red blood cell flow and transfusions might influence tiny blood vessel clots and organ problems in sepsis.
-
STeroids and enhanced Antibiotics for sepsis in Africa with HIV/TB (STARS)
This grant tests whether adding steroids and stronger antibiotics helps adults with severe sepsis tied to HIV/TB in areas with high TB rates.
-
Steroids and better antibiotics for sepsis in people with AIDS in Africa
This study tests whether adding hydrocortisone and stronger antibiotics can improve survival for adults with sepsis who also have AIDS or advanced immune suppression in regions with high TB.
-
Coordinating ARDS, Pneumonia, and Sepsis research to improve care
A national coordinating center helps researchers studying ARDS and related infections work together more efficiently to learn what helps patients recover.
-
Role of MMP3 in heart dysfunction during sepsis
This research tests whether blocking MMP3 can protect the heart and improve survival during sepsis in adults.
-
Sepsis patient care guided by Ugandan-wide immune profiling
A large NIH-funded study will map how the immune system behaves during sepsis in people in Uganda to improve personalized care for sepsis patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.